{
  "test_cases": {
    "pancreatic_cancer_advanced": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "FOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Advanced Pancreatic Cancer",
          "nctId": "NCT23456789",
          "officialTitle": "Randomized Phase III Trial Comparing FOLFIRINOX to Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy for Metastatic Pancreatic Adenocarcinoma"
        },
        "descriptionModule": {
          "briefSummary": "This phase III randomized trial compares the efficacy and safety of FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line treatment for metastatic pancreatic adenocarcinoma. Primary endpoint is overall survival.",
          "detailedDescription": "Patients with previously untreated metastatic pancreatic adenocarcinoma are randomized 1:1 to receive either FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, leucovorin) or gemcitabine plus nab-paclitaxel. The study aims to enroll 600 patients with stratification by performance status and liver metastases. Secondary endpoints include progression-free survival, response rate, and quality of life."
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma", "Advanced Pancreatic Cancer"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed pancreatic adenocarcinoma\n- Metastatic disease\n- No prior chemotherapy for metastatic disease\n- ECOG performance status 0-1\n- Adequate bone marrow, renal, and hepatic function\n- Measurable disease per RECIST 1.1\n\nExclusion Criteria:\n- Previous adjuvant chemotherapy within 6 months\n- Known dihydropyrimidine dehydrogenase deficiency\n- Active cardiac disease\n- Peripheral neuropathy ≥ grade 2"
        }
      }
    },
    "ovarian_cancer_recurrent": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "PARP Inhibitor Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer",
          "nctId": "NCT34567890",
          "officialTitle": "Phase III Study of Novel PARP Inhibitor as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer"
        },
        "descriptionModule": {
          "briefSummary": "This phase III trial evaluates the efficacy of a novel PARP inhibitor as maintenance therapy following response to platinum-based chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. Primary endpoint is progression-free survival.",
          "detailedDescription": "Patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy are randomized 2:1 to receive either the novel PARP inhibitor or placebo. The study includes biomarker analysis for homologous recombination deficiency status. Target enrollment is 450 patients."
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Recurrent Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed ovarian, fallopian tube, or primary peritoneal cancer\n- Platinum-sensitive recurrence (≥6 months since last platinum)\n- Complete or partial response to most recent platinum-based chemotherapy\n- ECOG performance status 0-1\n- Adequate organ function\n\nExclusion Criteria:\n- BRCA mutation known to confer PARP inhibitor resistance\n- Previous PARP inhibitor treatment\n- Active secondary malignancy\n- Uncontrolled brain metastases"
        }
      }
    },
    "glioblastoma_newly_diagnosed": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "TTFields Plus Temozolomide in Newly Diagnosed Glioblastoma",
          "nctId": "NCT45678901",
          "officialTitle": "Randomized Phase III Trial of Tumor Treating Fields Combined with Temozolomide Versus Temozolomide Alone in Patients with Newly Diagnosed Glioblastoma"
        },
        "descriptionModule": {
          "briefSummary": "This phase III randomized trial investigates whether the addition of tumor treating fields to standard temozolomide chemotherapy improves survival in patients with newly diagnosed glioblastoma. Primary endpoint is overall survival.",
          "detailedDescription": "Patients with newly diagnosed glioblastoma who have completed radiotherapy with concurrent temozolomide are randomized 1:1 to receive either maintenance temozolomide alone or temozolomide plus tumor treating fields. The study plans to enroll 700 patients with stratification by MGMT promoter methylation status and extent of resection."
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "GBM", "Brain Cancer", "Malignant Glioma"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed glioblastoma\n- Completed radiotherapy with concurrent temozolomide\n- Karnofsky performance status ≥70\n- Adequate bone marrow and organ function\n- Stable or responding disease after chemoradiation\n\nExclusion Criteria:\n- Previous chemotherapy for glioblastoma other than temozolomide\n- Implanted electronic devices in the brain\n- Skin conditions preventing TTFields application\n- Active infection"
        }
      }
    },
    "bladder_cancer_muscle_invasive": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer",
          "nctId": "NCT56789012",
          "officialTitle": "Phase II/III Study of Neoadjuvant Anti-PD-L1 Antibody Plus Chemotherapy Versus Chemotherapy Alone in Muscle-Invasive Bladder Cancer"
        },
        "descriptionModule": {
          "briefSummary": "This phase II/III trial evaluates the efficacy of adding anti-PD-L1 antibody to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Primary endpoint is pathological complete response rate.",
          "detailedDescription": "Patients with clinically localized muscle-invasive bladder cancer (T2-T4a N0 M0) are randomized to receive either neoadjuvant chemotherapy (gemcitabine/cisplatin) alone or chemotherapy plus anti-PD-L1 antibody. The phase II portion assesses safety and preliminary efficacy, with phase III expansion based on promising results. Biomarker analysis includes PD-L1 expression and tumor mutational burden."
        },
        "conditionsModule": {
          "conditions": ["Bladder Cancer", "Muscle-Invasive Bladder Cancer", "Urothelial Carcinoma", "Transitional Cell Carcinoma"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed muscle-invasive urothelial carcinoma of bladder\n- Clinical stage T2-T4a N0 M0\n- Planned radical cystectomy\n- Adequate renal function for cisplatin\n- ECOG performance status 0-1\n\nExclusion Criteria:\n- Previous systemic therapy for bladder cancer\n- Active autoimmune disease\n- Upper tract urothelial carcinoma\n- Uncontrolled cardiovascular disease"
        }
      }
    },
    "multiple_myeloma_relapsed": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma",
          "nctId": "NCT67890123",
          "officialTitle": "Phase II Study of BCMA-Directed CAR-T Cell Therapy in Patients with Triple-Class Refractory Multiple Myeloma"
        },
        "descriptionModule": {
          "briefSummary": "This phase II single-arm trial evaluates the efficacy and safety of BCMA-directed chimeric antigen receptor T-cell therapy in patients with multiple myeloma refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. Primary endpoint is overall response rate.",
          "detailedDescription": "Patients with triple-class refractory multiple myeloma receive lymphodepleting chemotherapy followed by infusion of autologous BCMA-directed CAR-T cells. The study includes comprehensive biomarker analysis including minimal residual disease assessment by next-generation sequencing. Target enrollment is 100 patients with extensive safety monitoring for cytokine release syndrome and neurotoxicity."
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Relapsed Multiple Myeloma", "Refractory Multiple Myeloma", "Plasma Cell Myeloma"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Documented multiple myeloma\n- Refractory to proteasome inhibitor, IMiD, and anti-CD38 antibody\n- Measurable disease\n- Adequate organ function\n- ECOG performance status 0-1\n- ≥3 prior lines of therapy\n\nExclusion Criteria:\n- Previous CAR-T cell therapy\n- Active CNS involvement\n- Uncontrolled infection\n- LVEF <40%\n- Creatinine clearance <30 mL/min"
        }
      }
    },
    "head_neck_cancer_recurrent": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "Anti-PD-1 Plus Cetuximab in Recurrent/Metastatic Head and Neck Cancer",
          "nctId": "NCT78901234",
          "officialTitle": "Randomized Phase II Trial of Anti-PD-1 Antibody Plus Cetuximab Versus Cetuximab Alone in Platinum-Refractory Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"
        },
        "descriptionModule": {
          "briefSummary": "This phase II randomized trial compares the efficacy of anti-PD-1 antibody plus cetuximab versus cetuximab alone in patients with platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma. Primary endpoint is overall survival.",
          "detailedDescription": "Patients with recurrent/metastatic head and neck squamous cell carcinoma that has progressed on platinum-based chemotherapy are randomized 1:1 to receive either cetuximab alone or cetuximab plus anti-PD-1 antibody. The study includes biomarker analysis for PD-L1 expression, HPV status, and tumor mutational burden. Target enrollment is 180 patients."
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Cancer", "Squamous Cell Carcinoma of Head and Neck", "Recurrent Head and Neck Cancer", "Metastatic Head and Neck Cancer"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed head and neck squamous cell carcinoma\n- Recurrent/metastatic disease\n- Progression on platinum-based chemotherapy\n- Measurable disease per RECIST 1.1\n- ECOG performance status 0-1\n- Adequate organ function\n\nExclusion Criteria:\n- Previous anti-PD-1/PD-L1 therapy\n- Previous cetuximab treatment\n- Active autoimmune disease\n- Severe hypersensitivity to monoclonal antibodies"
        }
      }
    },
    "gastric_cancer_advanced": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "Immunotherapy Plus Chemotherapy in Advanced Gastric/GEJ Cancer",
          "nctId": "NCT89012345",
          "officialTitle": "Phase III Study of Anti-PD-1 Antibody Combined with Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma"
        },
        "descriptionModule": {
          "briefSummary": "This phase III randomized trial evaluates the efficacy of adding anti-PD-1 antibody to standard chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma. Primary endpoints are overall survival and progression-free survival.",
          "detailedDescription": "Patients with previously untreated advanced gastric or GEJ adenocarcinoma are randomized 1:1 to receive either chemotherapy (fluoropyrimidine plus platinum) alone or chemotherapy plus anti-PD-1 antibody. The study includes comprehensive biomarker analysis including PD-L1 expression, microsatellite instability status, and Epstein-Barr virus status. Target enrollment is 800 patients."
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Stomach Cancer", "Gastroesophageal Junction Cancer", "GEJ Cancer", "Adenocarcinoma of Stomach"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed gastric or GEJ adenocarcinoma\n- Unresectable advanced or metastatic disease\n- No prior systemic therapy for advanced disease\n- Measurable disease per RECIST 1.1\n- ECOG performance status 0-1\n- Adequate organ function\n\nExclusion Criteria:\n- HER2-positive disease\n- Active autoimmune disease\n- Previous anti-PD-1/PD-L1 therapy\n- Uncontrolled brain metastases"
        }
      }
    },
    "renal_cell_carcinoma_advanced": {
      "protocolSection": {
        "identificationModule": {
          "briefTitle": "IO/TKI Combination in Treatment-Naive Advanced Renal Cell Carcinoma",
          "nctId": "NCT90123456",
          "officialTitle": "Randomized Phase III Trial of Immunotherapy Plus Tyrosine Kinase Inhibitor Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma"
        },
        "descriptionModule": {
          "briefSummary": "This phase III randomized trial compares the efficacy of combination immunotherapy plus tyrosine kinase inhibitor versus sunitinib as first-line treatment for advanced renal cell carcinoma. Primary endpoint is overall survival.",
          "detailedDescription": "Patients with previously untreated advanced clear cell renal cell carcinoma are randomized 1:1 to receive either sunitinib (standard care) or combination therapy with anti-PD-1 antibody plus TKI. The study includes International Metastatic RCC Database Consortium risk stratification and comprehensive biomarker analysis. Target enrollment is 1000 patients."
        },
        "conditionsModule": {
          "conditions": ["Renal Cell Carcinoma", "Kidney Cancer", "Advanced RCC", "Clear Cell Renal Cell Carcinoma"]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed clear cell renal cell carcinoma\n- Advanced or metastatic disease\n- No prior systemic therapy for advanced disease\n- Measurable disease per RECIST 1.1\n- ECOG performance status 0-1\n- Adequate organ function\n\nExclusion Criteria:\n- Non-clear cell histology\n- Active autoimmune disease\n- Uncontrolled hypertension\n- Previous organ transplantation"
        }
      }
    }
  }
}